Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Mirum Pharmaceuticals, Inc. clinical trials
The registry lists 39 studies whose lead sponsor is Mirum Pharmaceuticals, Inc.. 6 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 19, 2026.
Keep track of what changes. Save the Mirum Pharmaceuticals, Inc. studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Mirum Pharmaceuticals, Inc..
- Mirum Pharmaceuticals, Inc.39 studiesSame company
Something wrong?
Focus areas
Conditions Mirum Pharmaceuticals, Inc. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 39 of 39.
- Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)RecruitingNCT06193928
- A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)RecruitingNCT07200908Phase 3
- Study of MRM-3379 in Male Participants With Fragile X Syndrome (BLOOM)RecruitingNCT07209462Phase 2
- MRX-901: An Open-label Study to Assess Safety and Tolerability of Maralixibat in Participants With Intrahepatic Cholestasis of Pregnancy (ICP)Not yet recruitingNCT07823127Phase 2
- Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving BulevirtideRecruitingNCT07454837Phase 2/3
- Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)RecruitingNCT07290257Phase 4
- A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)Active, not recruitingNCT04663308Phase 2
- A Study to Evaluate the Absorption, Distribution, Metabolism, and Excretion of [14C]-MRM-3379CompletedNCT07712718Phase 1
- Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Disease (EXPAND)Active, not recruitingNCT06553768Phase 3
- A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary CholangitisActive, not recruitingNCT05050136Phase 2
- The REPLACE Registry for Cholbam® (Cholic Acid)Active, not recruitingNCT03115086
- A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)Active, not recruitingNCT07298330Phase 3
- An Extension Study of Maralixibat in Patients With Progressive Familial Intrahepatic Cholestasis (PFIC)CompletedNCT04185363Phase 3
- A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS).CompletedNCT04729751Phase 2
- A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta InfectionActive, not recruitingNCT06907290Phase 2/3
- MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat StudyCompletedNCT04168385Phase 2
- Evaluation of Maralixibat in Biliary Atresia Response Post-KasaiCompletedNCT04524390Phase 2
- Study to Evaluate Patients With Cerebrotendinous Xanthomatosis (RESTORE)CompletedNCT04270682Phase 3
- A Placebo-controlled Study of Volixibat in Subjects With Elevated Serum Bile Acids Associated With Intrahepatic Cholestasis of Pregnancy (OHANA)TerminatedNCT04718961Phase 2
- A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC)CompletedNCT03905330Phase 3
- Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic CholestasisCompletedNCT02057718Phase 2
- Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic AcidCompletedNCT00007020Phase 3
- Efficacy of To Be Marketed (TBM) Cholic Acid Capsules Used to Treat Children With Inborn Errors of Bile Acid SynthesisCompletedNCT01115582Phase 3
- Open Label, Continuation Study of Cholic Acid in Subjects With Inborn Errors of Bile Acid SynthesisCompletedNCT01438411Phase 3
- An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS)CompletedNCT02047318Phase 2
- A Maralixibat Expanded Access Program for Patients With Cholestatic Pruritus Associated With Alagille Syndrome (ALGS)Approved for marketingNCT04530994
- Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS)CompletedNCT02160782Phase 2
- An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille SyndromeCompletedNCT02117713Phase 2
- Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH)TerminatedNCT02787304Phase 2
- A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One DoseCompletedNCT02571192Phase 1
- Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid ExcretionCompletedNCT02475317Phase 1
- Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing CholangitisCompletedNCT02061540Phase 2
- Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille SyndromeCompletedNCT01903460Phase 2
- Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary CirrhosisCompletedNCT01904058Phase 2
- Evaluation of LUM001 in the Reduction of Pruritus in Alagille SyndromeCompletedNCT02057692Phase 2
- Safety and Tolerability Study of SHP626 in Overweight and Obese AdultsCompletedNCT02287779Phase 1
- An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary CirrhosisWithdrawnNCT02321306Phase 2
- Validation of the Itch Reported Outcome (ItchRO) Diaries in Pediatric Cholestatic Liver DiseaseCompletedNCT02131623
- A Placebo-controlled Study of Maralixibat (SHP625) in Pediatric Subjects With Progressive Familial Intrahepatic Cholestasis (PFIC)WithdrawnNCT03353454Phase 3